2-Chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide (namodenoson)


On 9 October 2015, orphan designation (EU/3/15/1565) was granted by the European Commission to PBS Regulatory Consulting Group Limited, United Kingdom, for 2-chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide for the treatment of hepatocellular carcinoma.

The sponsorship was transferred to Southwood Research Ltd in March 2020.

This medicine is now known as namodenoson. 

The sponsor's address was updated in June 2021.

Key facts

Active substance
2-Chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide (namodenoson)
Intented use
Treatment of hepatocellular carcinoma
Date of designation
Orphan designation status
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Southwood Research Ltd
Weesperstraat 61
1018 VN Amsterdam
Tel. +31 207997405

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating